Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
Coherus BioSciences (Nasdaq: CHRS) announced that senior management will present at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Coherus BioSciences (Nasdaq: CHRS) announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 8:15 a.m. PT. The presentation will include a Q&A session and can be accessed via webcast, available for replay until February 10, 2023. As a commercial-stage biopharmaceutical company, Coherus focuses on innovative immunotherapies for cancer treatment and has a portfolio of FDA-approved therapeutics.
Details
News Market Reaction – CHRS
The recorded move for CHRS in the trading session of this news was +15.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/upcoming-events. This webcast will be available for replay until February 10, 2023.
About Coherus
Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics.
Coherus Contact Information:
Marek Ciszewski, J.D.
SVP Investor Relations
Coherus Biosciences, Inc.
IR@coherus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.